



FOR IMMEDIATE RELEASE

CONTACT:
Kelly Sladek
SCORR Marketing
Kelly@scormarketing.com
308-237-5567

Dr. Unger Named Vice President and Laboratory Director of CEDRA Corporation

(February 16, 2010; Austin, TX) — [CEDRA Corporation](#), a provider of Phase I clinical research and bioanalytical services, announced that Steve E. Unger, Ph.D., has joined the CEDRA team as Vice President and Laboratory Director.

“Steve’s reputation and extensive experience in the pharmaceutical industry, along with his excellent management skills, make him an exceptional fit for CEDRA. He will be a valuable asset to CEDRA in the future, and we are fortunate that Dr. Unger is joining the team,” stated CEDRA CEO David B. Garcia, Ph.D.

Previously, Dr. Unger held the position of Senior Director in the areas of bioanalytical chemistry and drug metabolism at Wyeth (now Pfizer), where he managed scientists who performed high through-put bioanalysis in support of a number of drug candidates. Before joining Wyeth, Dr. Unger held a number of leadership positions at Bristol-Myers Squibb from 2001 until 2008. While at Bristol-Myers Squibb, Dr. Unger supervised and managed a team of scientists performing LC/MS bioanalysis that supported preclinical and clinical projects in addition to being responsible for the transfer of analytical methodology to various CROs.

About CEDRA

CEDRA Corporation, part of Worldwide Clinical Trials, offers a full range of Phase I-IIb [clinical research](#) and [bioanalytical](#) services, as well as [specialized studies](#) to the pharmaceutical/biotech and medical device industries. CEDRA’s combination of a state-of-the-art bioanalytical laboratory with clinical research sites allows them to play an important role in drug development programs. To learn more about CEDRA, visit www.cedracorp.com.

###